INTRODUCTION
The 4 most commonly diagnosed cancers in the Nordic European countries in 2020 were lung, breast, prostate, and colorectal, accounting for almost half of all cancer diagnoses (175,925).1 The estimated global incidence of cancer per 100,000 population in 2020 in Denmark was 350; Norway, 325; Sweden, 285; Finland, 270; and Iceland, 260.2
According to the Swedish National Cancer Register, these statistics exclude skin cancer, which comes in third place after breast and prostate cancers.2 Basal cell cancer accounts yearly for more than breast and prostate cancers for over 50,000 new cases versus 10,000 and 9,000 cases, respectively.2 Increasingly, more patients live with or survive cancer due to an early diagnosis and an improved quality of cancer treatment.3
In the Nordic European countries in 2010, the relative 5-year cancer survival percentage of males and females in Sweden was 70% and 69%; in Finland, 65% and 68%; Denmark was 62% and 65%; respectively, and in Norway for either gender, 69%.3
More people live with or survive cancer and have cancer treatment-related cAEs or sequelae.4-9,13-29 Cancer treatment-related cutaneous adverse events (cAEs) frequently occur, interfering with anticancer treatment outcomes and severely impacting quality of life (QoL) for patients.4,5,21-23,30-39 However, cAEs may indicate a therapeutic response.36
Patients most frequently report dermatologic adverse events as negatively impacting their QoL.6 The cAEs were unanticipated before therapy, and 67% of patients reported that cAEs were worse than their initial belief before starting cancer treatment despite the information given by health care providers.6 Another study showed that 58% of patients rated chemotherapy-induced alopecia as their therapy's most traumatic side effect, and 8%
According to the Swedish National Cancer Register, these statistics exclude skin cancer, which comes in third place after breast and prostate cancers.2 Basal cell cancer accounts yearly for more than breast and prostate cancers for over 50,000 new cases versus 10,000 and 9,000 cases, respectively.2 Increasingly, more patients live with or survive cancer due to an early diagnosis and an improved quality of cancer treatment.3
In the Nordic European countries in 2010, the relative 5-year cancer survival percentage of males and females in Sweden was 70% and 69%; in Finland, 65% and 68%; Denmark was 62% and 65%; respectively, and in Norway for either gender, 69%.3
More people live with or survive cancer and have cancer treatment-related cAEs or sequelae.4-9,13-29 Cancer treatment-related cutaneous adverse events (cAEs) frequently occur, interfering with anticancer treatment outcomes and severely impacting quality of life (QoL) for patients.4,5,21-23,30-39 However, cAEs may indicate a therapeutic response.36
Patients most frequently report dermatologic adverse events as negatively impacting their QoL.6 The cAEs were unanticipated before therapy, and 67% of patients reported that cAEs were worse than their initial belief before starting cancer treatment despite the information given by health care providers.6 Another study showed that 58% of patients rated chemotherapy-induced alopecia as their therapy's most traumatic side effect, and 8%
